

June 8, 2023

BSE Limited Code: 532321

P J Towers, Dalal Street, Mumbai-400001

National Stock Exchange of India Limited

Exchange Plaza, C/1, Block G, Bandra-Kurla Complex, Bandra (East), Mumbai-400051

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated June 8, 2023 titled "Zydus receives final approval from the USFDA for Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg and 40 mg".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, ZYDUS LIFESCIENCES LIMITED

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above



Code: Zyduslife



Zydus receives final approval from the USFDA for Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg and 40 mg

Ahmedabad, India, 8 June, 2023

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) for Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg and 40 mg (USRLD: Nexium Delayed-Release for Oral Suspension, 20 mg and 40 mg).

Esomeprazole is used to treat certain stomach and esophagus problems (such as acid reflux and ulcer). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as heartburn, difficulty swallowing, and cough. This medication helps heal acid damage to the stomach and esophagus, helps prevent ulcers and is expected to help prevent cancer of the esophagus. Esomeprazole belongs to a class of drugs known as proton pump inhibitors (PPIs). The product will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad (India).

Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg and 40 mg had annual sales of USD 42 mn in the United States (IQVIA MAT April 2023).

The group now has 370 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.

(*as of 31st March 2023)



For further information please contact: The Corporate Communications Department

Zydus Lifesciences Limited

(formerly known as Cadila Healthcare Limited)

Regd. Office: 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, Gujarat, India. | Phone: +91-79-71800000, +91-79-48040000 | website: www.zyduslife.com CIN: L24230GJ1995PLC025878